Reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-09 and is reviewed periodically as new material appears.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Recent advancements in bioorthogonal chemistry have revealed applications in protein analysis. The extension of using organic molecules to observe their reaction with proteins reveals extensive methods to tag them. Unnatural amino acids and various functional groups represent new growing technologies in proteomics. Specific biomolecules that are capable of being metabolized in cells or tissues are inserted into proteins or glycans. The molecule will have an affinity tag, modifying the protein allowing it to be detected. Azidohomoalanine (AHA) utilizes this affinity tag via incorporation with Met-t-RNA synthetase to incorporate into proteins. This has allowed AHA to assist in determine the identity of newly synthesized proteins created in response to perturbations and to identify proteins secreted by cells. Recent studies using ketones and aldehydes condensations show that they are best suited for in vitro or cell surface labeling. However, using ketones and aldehydes as bioorthogonal reporters revealed slow kinetics indicating that while effective for labeling, the concentration must be high. Certain proteins can be detected via their reactivity to azide groups. Non-proteinogenic amino acids can bear azide groups which react with phosphines in Staudinger ligations. This reaction has already been used to label other biomolecules in living cells and animals. The bioorthogonal field is expanding and is driving further applications within proteomics. It is worthwhile noting the limitations and benefits.
=== Absorbed dose and dose equivalent === The British physicist and radiologist and founder of radiobiology Louis Harold Gray (1905-1965) introduced the unit Rad (acronym for radiation absorbed dose) in the 1930s, which was renamed Gray (Gy) after him in 1978. One gray is a mass-specific quantity and corresponds to the energy of one joule absorbed by one kilogram of body weight. Acute whole-body exposures in excess of four Gy are usually fatal to humans. The different types of radiation ionize to different degrees. Ionization is any process in which one or more electrons are removed from an atom or molecule, leaving the atom or molecule as a positively charged ion (cation). Each type of radiation is therefore assigned a dimensionless weighting factor that expresses its biological effectiveness. For X-rays, gamma and beta radiation, the factor is one, alpha radiation reaches a factor of twenty, and for neutron radiation it is between five and twenty, depending on the energy. Multiplying the absorbed dose in Gy by the weighting factor gives the equivalent dose, expressed in Sievert (Sv). It is named after the Swedish physician and physicist Rolf Maximilian Sievert (1896-1966). Sievert was the founder of radiation protection research and developed the Sievert chamber in 1929 to measure the intensity of X-rays. He founded the International Commission on Radiation Units and Measurements (ICRU) and later became chairman of the International Commission on Radiological Protection (ICRP).
== Ecology == In nature, A. roeperi is found primarily on the walls of ambrosia beetle galleries within a wide variety of host trees, where it survives by degrading compounds within wood. Traditionally, although they facilitate beetle growth and reproduction in nutritionally poor xylem tissue, ambrosia fungi are considered to be ineffective agents of wood decomposition, producing enzymes primarily dedicated to degradation of xylan, glucomannan, and callose (common components of hemicellulose) rather than cellulose, mirroring similar analyses made for various saprotrophic fungi. However, no equivalent studies have been performed on A. roeperi specifically, and it is worth noting that the article often cited in support of this conclusion only examined the fungal galleries of one beetle (Xyleborinus saxenii) associated with a different symbiont, Raffaelea sulfurea. Interestingly, metabolomic studies incorporating A. roeperi indicate that when growing on wood, this fungus possesses a lipid profile more similar to non-mutualistic Ceratocystidaceae than to other ambrosia fungi, further supporting the idea that making sweeping conclusions about fungal lifestyles based on data from apparently similar convergent systems can be misleading, as well as reinforcing how much remains to be learned about this and other ambrosial species. There are various molecular indications that hint at other ways in which A. roeperi may interact with its woody hosts.
The engagement of KOR during chronic pain states, particularly neuropathic pain, has been implicated in the high comorbidity between chronic pain and mood disorders, as dynorphin-mediated KOR signaling in limbic and reward-related brain regions drives negative emotional states and anhedonia.
=== Pharmacokinetics === The two active components of the medication, ibuprofen and hydrocodone, do not affect each other's absorption characteristics or other pharmacokinetic parameters. After an oral dose, the peak level of hydrocodone in the blood is reached 1.7 hours after administration. The blood levels of ibuprofen peak 1.8 hours after oral administration.
Sources: en.wikipedia.org
type of shadowing (lines, dots or rings) reticular (crisscrossing lines) companion shadow (lines paralleling bony landmarks) nodular (many small dots) rings or cysts ground glass consolidation (diffuse opacity with air bronchograms) location (where is the lesion worst?) upper (e.g., sarcoid, tuberculosis, silicosis/pneumoconiosis, ankylosing spondylitis, Langerhans cell histiocytosis) lower (e.g., cryptogenic fibrosing alveolitis, connective tissue disease, asbestosis, drug reactions) central (e.g., pulmonary edema, alveolar proteinosis, lymphoma, Kaposi's sarcoma, PCP) peripheral (e.g., cryptogenic fibrosing alveolitis, connective tissue disease, chronic eosinophilic pneumonia, bronchiolitis obliterans organizing pneumonia) lung volume increased (e.g., Langerhans cell histiocytosis, lymphangioleiomyomatosis, cystic fibrosis, allergic bronchopulmonary aspergillosis) decreased (e.g., fibrotic lung disease, chronic sarcoidosis, chronic extrinsic allergic alveolitis) Pleural effusions may occur with cancer, sarcoid, connective tissue diseases and lymphangioleiomyomatosis. The presence of a pleural effusion argues against pneumocystis pneumonia.
=== Location === The SA node is located in the wall (epicardium) of the right atrium, laterally to the entrance of the superior vena cava in a region called the sinus venarum (hence sino- + atrial). It is positioned roughly between a groove called the crista terminalis located on the internal surface of the heart and the corresponding sulcus terminalis, on the external surface. These grooves run between the entrance of the superior vena cava and the inferior vena cava.
In 1H Magnetic Resonance Spectroscopy each proton can be visualized at a specific chemical shift (peak position along x-axis) depending on its chemical environment. This chemical shift is dictated by neighboring protons within the molecule. Therefore, metabolites can be characterized by their unique set of 1H chemical shifts. The metabolites that MRS probes for have known (1H) chemical shifts that have previously been identified in NMR spectra. These metabolites include:
The idea of "no independence before majority rule", commonly abbreviated to "NIBMAR", gained considerable ground in British political circles. When Huggins (who had been recently ennobled as Lord Malvern) asked Britain to make the Federation a dominion in 1956, he was rebuffed. The opposition Dominion Party responded by repeatedly calling for a Federal unilateral declaration of independence (UDI) over the next few years. Following Lord Malvern's retirement in late 1956, his successor Sir Roy Welensky pondered such a move on at least three occasions. Attempting to advance the case for Southern Rhodesian independence, particularly in the event of Federal dissolution, the Southern Rhodesian Prime Minister Sir Edgar Whitehead brokered the 1961 constitution with Britain, which he thought would remove all British powers of reservation over Southern Rhodesian bills and acts, and put the country on the brink of full sovereignty. Despite its containing no independence guarantees, Whitehead, Welensky and other proponents of this constitution presented it to the Southern Rhodesian electorate as the "independence constitution" under which Southern Rhodesia would become a dominion on a par with Australia, Canada and New Zealand if the Federation dissolved. White dissenters included Ian Smith, MP for Gwanda and Chief Whip for the governing United Federal Party (UFP) in the Federal Assembly, who took exception to the constitution's omission of an explicit promise of Southern Rhodesian independence in the event of Federal dissolution, and ultimately resigned his post in protest.
== 16α-Hydroxylation == Through the action of CYP1A1, CYP1A2, CYP2C8, and the CYP3A isoforms, 16α-hydroxyestradiol (16α-OHE2), also known as estriol, is produced in abundance during pregnancy. 16α-OHE2 can be dehydrogenated to 16α-hydroxyestrone (16α-OHE1), a metabolite that has been shown to bind covalently to the estrogen receptor via Schiff base formation. This covalent linkage occurs between the steroid carbonyl and the ε-amino group of lysine. In theory, 16α-OHE1 could also bind DNA, although this has not been observed. 16α-OHE2 is a potent ER agonist, capable of levels of cellular proliferation stimulation that near those obtained with E2. Though studies in hamster kidney tumor models showed weak carcinogenicity, the carcinogenic potential of 16α-OHE2 in humans remains unknown.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.